Viridian Therapeutics, Inc. (VRDN)

Name: Viridian Therapeutics, Inc. (VRDN) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

SEC name Viridian Therapeutics, Inc.\DE · CIK 0001590750 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Viridian Therapeutics, Inc. reported revenue of $70.85M. Over the twelve months to 2026-06-30, revenue was $71.13M.

Key ratios (year ended 2025-12-31)

-512.9%

Operating margin

-483.6%

Net margin

-47.4%

Return on year-end equity

n/m

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-08-20

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$71.13M	$70.85M	$302.0K	$314.0K	$1.77M	$2.96M	$1.05M	$4.46M	$8.39M	$4.00M	$3.48M
Cost of Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$2.55M
Gross Profit (computed)	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$929.0K
R&D Expense	$324.68M	$338.93M	$238.25M	$159.76M	$100.89M	$56.89M	$28.30M	$34.79M	$30.42M	$19.62M	$13.69M
Operating Income	-$405.20M	-$363.39M	-$299.04M	-$254.45M	-$134.30M	-$79.73M	-$110.38M	-$41.98M	-$33.08M	-$26.53M	-$16.99M
Depreciation & Amortization	$468.0K	$460.0K	$540.0K	$522.0K	$255.0K	$120.0K	$239.0K	$288.0K	$281.0K	$308.0K	$341.0K
EBITDA	-$404.73M	-$362.94M	-$298.50M	-$253.93M	-$134.05M	-$79.61M	-$110.14M	-$41.69M	-$32.80M	-$26.22M	-$16.65M
Net Income	-$386.97M	-$342.60M	-$269.95M	-$237.73M	-$129.87M	-$79.41M	-$110.72M	-$41.87M	-$32.70M	-$26.51M	-$17.27M
EPS (Diluted)	n/a	n/a	n/a	-$5.31	-$4.05	-$6.66	-$31.13	n/a	n/a	n/a	n/a
Total Assets	$1.10B	$899.42M	$742.40M	$490.42M	$435.09M	$203.71M	$131.25M	$30.26M	$66.15M	$52.48M	$24.76M
Total Liabilities	$435.14M	$177.25M	$70.76M	$48.40M	$40.03M	$15.99M	$11.22M	$14.51M	$14.80M	$13.97M	$9.71M
Long-Term Debt	n/a	n/a	n/a	$20.20M	$4.64M	$0	n/a	$7.67M	$10.00M	$10.00M	n/a
Shareholders' Equity	$662.10M	$722.17M	$671.64M	$442.02M	$395.06M	$187.72M	$120.04M	$15.75M	$51.34M	$38.51M	-$61.92M
Cash & Equivalents	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$32.61M	$47.44M	$22.10M
Operating Cash Flow	-$333.34M	-$276.39M	-$232.32M	-$184.17M	-$93.84M	-$54.58M	-$29.78M	-$36.06M	-$26.84M	-$28.17M	-$14.76M
Capital Expenditures	$1.70M	$495.0K	$511.0K	$898.0K	$797.0K	$338.0K	$42.0K	$84.0K	$445.0K	$246.0K	$250.0K
Free Cash Flow	-$335.04M	-$276.89M	-$232.83M	-$185.07M	-$94.64M	-$54.92M	-$29.82M	-$36.14M	-$27.29M	-$28.41M	-$15.01M
Share Repurchases	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$2.0K
Shares Outstanding	113.24M	101.83M	80.99M	53.99M	41.31M	23.92M	4.23M	2.32M	30.84M	22.57M	833.7K
Weighted Average Diluted Shares	n/a	n/a	n/a	44.76M	32.09M	11.92M	3.56M	n/a	n/a	n/a	n/a
EPS (Basic)	n/a	n/a	n/a	-$5.31	-$4.05	-$6.66	-$31.13	n/a	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView